z-logo
open-access-imgOpen Access
Cytotoxicity assessment of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) paste
Author(s) -
Sandra Kalil Bussadori,
Kristianne Porta Santos Fernandes,
Raquel Agnelli MesquitaFerrari,
Elaine Marcílio Santos,
Carolina Cardoso Guedes,
Lara Jansiski Motta,
Laura Hermida Bruno,
Diana Ram
Publication year - 2010
Publication title -
conscientiae saúde
Language(s) - English
Resource type - Journals
eISSN - 1983-9324
pISSN - 1677-1028
DOI - 10.5585/conssaude.v9i3.2224
Subject(s) - trypan blue , cytotoxicity , amorphous calcium phosphate , casein , viability assay , mtt assay , phosphopeptide , chemistry , calcium , mineral trioxide aggregate , phosphate , biochemistry , chromatography , food science , dentistry , cell , in vitro , phosphorylation , medicine , organic chemistry
Casein phosphopeptides (CPP) have been shown to be good carriers of calcium, phosphate, and hydroxide ions to promote enamel remineralization with applications in oral care products, professional dental products, and food products. Objectives: Evaluate the cytotoxicity of a casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) paste in rat fibroblasts. Materials and methods: Cytotoxicity was measured by the Trypan blue dye exclusion assay and the MTT assay. Results: Long term (1, 3, 5, and 7 days) and short term tests (0, 4, 8, and 12 hours) were performed with the Trypan blue dye exclusion assay. Data were analyzed with ANOVA and Kruskall Wallis tests. After one day, the cell viability of the CPP-ACP study group was between 80 and 100%. In the short term experiments, a reduction of cell viability in the study group was observed compared with the control group; yet viable cells were present over the evaluation period. With the MTT assay, a viability of 76.43% was observed in the study group, a significant difference from the control group (P = 0.003). Conclusion: CPP-ACP paste demonstrates low cytotoxicity in rat fibroblast culture.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here